Literature DB >> 24968088

Recombinant LH administration in subsequent cycle after "unexpected" poor response to recombinant FSH monotherapy.

Enrico Papaleo1, Valeria Stella Vanni, Paola Viganò, Antonio La Marca, Luca Pagliardini, Rossella Vitrano, Mara Zanirato, Elena Marsiglio, Laura Privitera, Massimo Candiani.   

Abstract

Abstract Poor ovarian response (POR) is most frequently linked to the condition known as diminished ovarian reserve, but it can also occur in the absence of pathological ovarian reserve tests ("unexpected" POR). Because possible explanations include theca cells function deficiency, our aim was to evaluate the effect of r-LH administration in "unexpected" poor responders. A retrospective, single-centre, cohort study was conducted on 65 patients with AMH >0.5 ng/ml and/or AFC >5 with POR in their first cycle. Patients underwent a second IVF cycle with same protocol (long- or antagonist) and same starting dose of r-FSH used in the first cycle, plus daily addiction of 150 IU of r-LH from day 1. Compared to the first cycle, r-LH addition in the second cycle determined an increase in number of oocytes retrieved (p < 0.001), number of metaphase II oocytes (p < 0.05), E2 levels at hCG triggering (p < 0.001) and number of embryos transferred (p = 0.002). A 15% clinical pregnancy rate was also observed in the second cycle. Our results suggest that patients with non-pathological ovarian reserve tests and previous "unexpected" POR seem to benefit from r-LH addition in subsequent cycles without the need to increase the r-FSH starting dose, possibly due to an underlying occult theca cells deficiency.

Entities:  

Keywords:  Controlled ovarian stimulation; poor ovarian response; recombinant LH; theca cells

Mesh:

Substances:

Year:  2014        PMID: 24968088     DOI: 10.3109/09513590.2014.932342

Source DB:  PubMed          Journal:  Gynecol Endocrinol        ISSN: 0951-3590            Impact factor:   2.260


  5 in total

1.  The Application of Dehydroepiandrosterone on Improving Mitochondrial Function and Reducing Apoptosis of Cumulus Cells in Poor Ovarian Responders.

Authors:  Li-Te Lin; Peng-Hui Wang; Zhi-Hong Wen; Chia-Jung Li; San-Nung Chen; Eing-Mei Tsai; Jiin-Tsuey Cheng; Kuan-Hao Tsui
Journal:  Int J Med Sci       Date:  2017-05-13       Impact factor: 3.738

2.  Management Strategies for POSEIDON's Group 1.

Authors:  Nikolaos P Polyzos; Panagiotis Drakopoulos
Journal:  Front Endocrinol (Lausanne)       Date:  2019-10-01       Impact factor: 5.555

3.  Early Follicular Phase Human Chorionic Gonadotropin Addition May Improve the Outcomes of In Vitro Fertilization/Intracytoplasmic Sperm Injection in Patients With "Unpredictable" Poor Response to Gonadotropin-Releasing Hormone Antagonist Protocol.

Authors:  Chunhui Zhang; Fangrong Wu; Zexuan Wu; Bolan Sun; Cheng Chen; Weiping Qian
Journal:  Front Endocrinol (Lausanne)       Date:  2021-10-11       Impact factor: 5.555

4.  The Effect of Dose Adjustments in a Subsequent Cycle of Women With Suboptimal Response Following Conventional Ovarian Stimulation.

Authors:  Panagiotis Drakopoulos; Samuel Santos-Ribeiro; Ernesto Bosch; Juan Garcia-Velasco; Christophe Blockeel; Alessia Romito; Herman Tournaye; Nikolaos P Polyzos
Journal:  Front Endocrinol (Lausanne)       Date:  2018-07-23       Impact factor: 5.555

5.  Immature oocyte incidence: Contributing factors and effects on mature sibling oocytes in intracytoplasmic sperm injection cycles.

Authors:  Daniela Paes de Almeida Ferreira Braga; Bianca Ferrarini Zanetti; Amanda Souza Setti; Assumpto Iaconelli; Edson Borges
Journal:  JBRA Assist Reprod       Date:  2020-01-30
  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.